Paris, France
International Symposium Sjögren’s Disease (ISSJD 2026)
June 27 - 30, 2026
Sjögren’s Disease (SjD)
Sjögren’s disease is a chronic, systemic autoimmune disorder characterized by lymphoid infiltration of exocrine glands and potential systemic manifestations.1-4
The symptoms can vary by patients and over the course of the disease.2 Common symptoms include xerostomia and keratoconjunctivitis.2,5 Many patients may also experience pain, fatigue, and various systemic manifestations, such as musculoskeletal or cutaneous involvement.4-7 Patients with SjD also have a higher risk of developing non-Hodgkins lymphoma than healthy individuals.8 Long-term damage can be disabling and lead to reduced quality of life.3
Upcoming Sjögren’s Disease Medical Congress Events
Our Latest Sjögren’s Disease Publications
Efficacy and safety of telitacicept in participants with Sjögren’s disease: Results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study
Telitacicept as a Novel BAFF/APRIL-Targeted Therapy for Sjögren’s Disease
References:
- Aguiñaga MDLG, et al. Int J Appl Dent Sci. 2022;8(2):155-159
- Both T, et al. Int J Med Sci. 2017;14(3):191-200
- Baldini C et al., Nat Rev Rheumatol.2024;20(8):473-491
- Zhao T, et al. Heliyon. 2024;10(17):e36220
- Vitali C, et al. Ann Rheum Dis. 2002;61(6):554-558
- Brito-Zerón P, et al. Expert Rev Clin Immunol. 2016;12(2):137-156
- Negrini S, et al. Clin Exp Med. 2022;22(1):9-25
- Chiu YH, et al. Oncotarget. 2017;8(30):50098-50108